Answers are grounded in this paper and cite their sources.
Neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease or Multiple Sclerosis are characterized by progressive loss of neuronal structure and function, and current therapies remain purely symptomatic, offering no disease-modifying benefit. This challenge has driven the development towards rationally designed 1,2,3-triazole hybrid molecules for the treatment and diagnosis of these disorders. 1,2,3-triazole derivatives are synthesized reliably through copper-catalyzed azide-alkyne cycloaddition, termed click reaction, and acting either as a stable structural linker between two independent pharmacophores or as an active pharmacological contributor. In this review, we provide a comprehensive overview of the recent development of 1,2,3-triazole derivatives investigated for Alzheimer’s disease, Parkinson’s disease and Multiple Sclerosis with particular emphasis on their structural features, biological targets and pharmacological properties. The reviewed compounds exhibit a broad range of activities relevant to neurodegeneration, including cholinesterase inhibition, adenosine receptor antagonism, modulation of oxidative stress and neuroinflammation, inhibition of protein aggregation, and interaction with disease-associated molecular targets. The versatility of the 1,2,3-triazole scaffold enables the combination of complementary pharmacophores and even the generation of multitarget-directed compounds. In addition, 1,2,3-triazole scaffolds facilitate blood brain barrier penetration and enhance drug metabolic stability. Overall, 1,2,3-triazole derivatives represent a versatile chemical platform for the exploration of multifunctional strategies against neurodegenerative disorders and provide opportunities for the future design of new therapeutic candidates.
No takes yet. Share an insight, caveat, or question.
Rubio-Sanz et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: